Pharmaceutical company Celltrion announced that the Food and Drug Administration had approved Eydenzelt to treat four retinal diseases.
Eydenzelt is approved for use in treating wet age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy.
In the 52-week phase 3 clinical trial, Eydenzelt proved to have the same therapeutic effect as Eylea for patients dealing with diabetic macular edema and Eydenzelt also proved to have similar efficacy and safety as Eylea. Eydenzelt is biosimilar to Eylea which means that it is highly similar to Eylea but will be a more affordable option for patients. Biosimilar drugs differ from generic drugs in that generic drugs are chemically identical to name brand drugs.
